Articles By Jack Cush, MD
CMS Releases Final Rule on Joint Replacement
MedPage Today reports that the Centers for Medicare & Medicaid Services (CMS) has issued a final rule governing payment for hip and knee replacements for Medicare patients this week that includes several concessions to stakeholders, such as delaying implementation from early 2016 to later in
Read Article
Opioid Use Ups the Risk of Hospitalized Infections in Rheumatoid Arthritis
Researchers from Vanderbilt University have studied the issue of opioid use in rheumatoid arthritis (RA) and whether this influences infection risk.
Read Article
Psoriasis May Not Be a Risk for CV Events
Patients with psoriatic skin and joint disease are uniquely susceptible to multiple comorbidities, obesity and possibly more cardiovascular risks. In rheumatoid arthritis, the increased CV risk and CV events have been closely aligned with inflammation and disease activity.
Read Article
AMA Proposes Ban on Television Drug Ads
The American Medical Association has called for a ban on direct-to-consumer (DTC) advertising for prescription drugs and medical devices, noting these forms of advertising drive up health care costs and often mislead the public.
Read Article
SB4 - A Second Biosimilar Up For Review in Europe
A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.
Read Article
Alcohol and Methotrexate - What Do You Advise?
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read Article
Tocilizumab & Abatacept Effective in Giant Cell Arteritis
Giant cell arteritis (GCA) is a medium and large vasculitis, wherein only glucocorticoids (GC) treatment has been the mainstay of therapy. As many will require prolonged treatment, the hazards of GC are well known, lead to substantial toxicity and morbidity.
Read Article
The Born Again Rheumatoid
While there are currently 9 biologic agents approved and marketed for the treatment of RA, and although each has a valued place in our arsenal, I would propose none has been as influential or dramatic as TNF inhibitors. The “born again” rheumatoid feeling is not well captured by any of the usual metrics or measures. It’s not found in the HAQ, DAS28, SF36 (either mental or physical), fatigue score, or any lab parameter. I believe it’s best described by my patient RH who wrote me a letter soon after starting etanercept.
Read Article
Are Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Read Article
Pharmacy Benefit Managers at Odds with Specialty Pharmacies
Reuters and the Wall Street Journal have reported that the largest U.S. pharmacy benefit managers (PBM) of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices.
Read Article